Autoimmune Diseases

In addition to the numerous adalimumab (Humira) biosimilars that launched this year, multiple new biosimilar products were approved by the FDA in 2023.

Most patients were not concerned about losing control over their disease after switching.

Authors of a platinum-ranked poster presented at AMCP Nexus 2023 suggested that the burden of increased spending on specialty medications varies by race and wage among employees with employer-sponsored health insurance.

Newly approved by the FDA, Celltrion’s infliximab-dyyb (Zymfentra) offers patients with inflammatory bowel disease a more innovative administrative approach to infliximab treatment.

Patients with rheumatoid arthritis had a higher risk of shingles when treated once a day with 4 mg of baricitinib, 100 mg of peficitinib, or 30 mg of upadacitinib.

Despite pleas from celiac disease advocates, the FDA still does not require drug manufacturers to note on the label whether a medication contains gluten.

Anti-TNF agents were found to increase the risk of autoimmune disease, especially in psoriasis and lupus.

These medications join adalimumab-atto, which launched on January 31.

Quality of life (QOL) for people living with autoimmune diseases benefits from an integrated approach that considers individual immune system sensitivities and patients’ life circumstances, a new study shows.

As more adalimumab biosimilars are poised to enter the market, manufacturers, payers, and patient advocates are preparing to navigate potentially turbulent waters.

Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.

Speakers at the 2023 virtual Value-Based Insurance Design Summit discussed government programs and company initiatives to advance health equity, as well as the role of research and advocacy to achieve pharmacoequity.

The launch of Amgen's adalimumab biosimilar Amjevita was just the start of a wave of biosimilars to treat autoimmune diseases.

Viruses are known to precipitate autoimmune diseases, but the link between COVID-19 and autoimmune conditions requires additional research.

As a dozen Humira Biosimilars are set to enter the market this year, it seems to be unlikely that they will drive down drug costs in the future.

Pharmacists are well positioned to address the care issues faced by patients living with autoimmune diseases.

While the use of combined oral contraceptives in patients with rheumatoid and autoimmune disorders have focused on safety, a recent narrative review highlighted the efficacy and benefits of these contraceptives in women with RA.

Managing autoimmune conditions like type 1 diabetes, rheumatoid arthritis, and lupus during pregnancy can present challenges for patients and physicians.

Healthcare professionals need to make patients the primary decision-makers in their own care and actively support their efforts to achieve their care goals.

Emerging evidence is changing health care providers’ approach to treating pediatric rheumatic diseases.

Investigators supplemented a slim body of existing research on CBD for pain management.

A study presented at ACR Convergence 2021 examined the relationship between race/ethnicity, living in a disadvantaged neighborhood, and how often patients are prescribed disease-specific treatments.

Drug Topics® sat down with Dr. Daniel Streetman, PharmD, to discuss patients with compromised immune systems and reported responses to COVID-19 vaccines and others.

Pharmacists can educate patients on psoriasis treatments and lifestyle modifications, address expected drug-related adverse effects (AEs), and improve medication adherence.

Anifrolumab (Saphnelo; AstraZeneca) significantly improves disease activity and reduces corticosteroid use in patients with SLE.

Individuals with irritable bowel syndrome with constipation indicated that although their symptoms worsened during the pandemic, they did not seek medical care.

Pharmacists must keep up to date with the latest in irritable bowel syndrome management.

At the virtual Scientific Sessions for the American Diabetes Association, a study shows that metformin can improve adolescent type 1 diabetes.

A study presented during a poster session at the American Diabetes Association Virtual 81st Scientific Sessions evaluated performance, safety, and satisfaction of an extended-wear insulin infusion set in patients with type 1 diabetes.

Aducanumab (Aduhelm; Biogen) is the first approved novel treatment for Alzheimer disease since 2003.